UK markets close in 3 hours 3 minutes
  • FTSE 100

    7,386.84
    -107.29 (-1.43%)
     
  • FTSE 250

    21,621.40
    -641.84 (-2.88%)
     
  • AIM

    1,090.96
    -41.12 (-3.63%)
     
  • GBP/EUR

    1.1928
    -0.0019 (-0.16%)
     
  • GBP/USD

    1.3490
    -0.0056 (-0.41%)
     
  • BTC-GBP

    24,897.12
    -1,812.42 (-6.79%)
     
  • CMC Crypto 200

    760.93
    +518.25 (+213.56%)
     
  • S&P 500

    4,397.94
    -84.79 (-1.89%)
     
  • DOW

    34,265.37
    -450.03 (-1.30%)
     
  • CRUDE OIL

    84.38
    -0.76 (-0.89%)
     
  • GOLD FUTURES

    1,840.90
    +9.10 (+0.50%)
     
  • NIKKEI 225

    27,588.37
    +66.11 (+0.24%)
     
  • HANG SENG

    24,656.46
    -309.09 (-1.24%)
     
  • DAX

    15,249.74
    -354.14 (-2.27%)
     
  • CAC 40

    6,908.11
    -160.48 (-2.27%)
     

Global Multiple Sclerosis Market – Analysis By Drug Class, Route of Administration, Distribution Channel, By Region, By Country : Market Insights, Pipeline and Forecast with Impact of COVID-19

·3-min read

Executive Summary The Global Multiple Sclerosis Market is estimated at USD 26. 01 Billion in the year 2020. The introduction of disease-modifying drugs as a treatment option is a key factor that drives the growth of the global multiple sclerosis market.

New York, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Multiple Sclerosis Market – Analysis By Drug Class, Route of Administration, Distribution Channel, By Region, By Country : Market Insights, Pipeline and Forecast with Impact of COVID-19" - https://www.reportlinker.com/p06195734/?utm_source=GNW
Various technological advancements, such as the development of innovative monoclonal bodies, immuno-modulators, immunosuppressants and interferons for the effective treatment of MS, are acting as major growth-inducing factors. Moreover, the growth of the global multiple sclerosis market is driven by a shift in preference toward oral drugs. Also, an increase in the number of pipeline drugs is anticipated to offer lucrative opportunities for market expansion during the forecast period.

The expansion of the Multiple Sclerosis Market is encouraged by government and non-government organizations. The government and non-governmental organizations support a variety of initiatives and programs to help persons with multiple sclerosis improve their quality of life (MS).

The global multiple sclerosis market size is set to gain traction as many leading pharmaceutical companies are conducting clinical trials to discover innovative and effective therapies for the treatment of this immune disorder. In addition, clinical studies for the treatment of multiple sclerosis are being conducted by several pharmaceutical companies. Companies are working to create novel medicines in multiple sclerosis radiology for patients suffering from the condition which is further driving the growth of the market.

Scope of the Report
• The report analyses the Multiple Sclerosis Market for the historical period 2016-2020 and the forecast period of 2021-2026.

• The report analyses the Multiple Sclerosis Market by Value (USD Million).

• The report analyses the Multiple Sclerosis Market Drug Class (Immunomodulators, Immunosuppressants, Interferons, Others).

• The report analyses the Multiple Sclerosis Market by Route of Administration (Oral, Injectable, Intravenous).

• The report analyses the Multiple Sclerosis Market Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy).

• The Global The report analyses the Multiple Sclerosis Market by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy).

• Market has been analysed By Region (North America, Europe, Asia Pacific, LAMEA) By Country (United States, Canada, Germany, U.K, France, Italy, China, Japan, India, South Korea).

• The key insights of the report have been presented through the frameworks of the attractiveness of the market has been presented by region, by Drug Class, by Route of Administration, by Distribution Channel.

• Also, the major opportunities, trends, drivers and challenges of the industry has been analysed in the report.

• The report tracks competitive developments, strategies, Pipelines and new product development. The companies analysed in the report include Bristol-Myers Squibb, F. Hoffman-La Roche, Ltd., Pfizer Inc., GlaxoSmithKline, Novartis AG, Teva Pharmaceuticals Industries Limited, BAYER AG, Biogen, EMD Sereno, NervGen Pharma.

Key Target Audience

• Healthcare and Pharmaceutical Companies

• Consulting and Advisory Firms

• Government and Policy Makers

• Regulatory Authorities
Read the full report: https://www.reportlinker.com/p06195734/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting